

Elekta wins majority of Italian public tender for advanced cancer care

STOCKHOLM – Elekta (EKTA-B.ST) announces that it has been selected to deliver 37 Versa HD linear accelerators (linacs) for a total value of approximately EUR 50 million to Servizio Sanitario Nazionale, Italy's national health service. This corresponds to 60 percent of the linac tender. The order is expected to be booked during Elekta's third and fourth quarters of fiscal year 2023/24. The installations are expected to be completed in fiscal years 2023/24 and 2024/25.

Ardie Ermers, Elekta's Executive Vice President, Region Europe says: "We are extremely pleased to see more national, regional and local health care providers in Europe choosing Elekta to provide cancer treatment for their patients. For Italy, it means a modernization of the country's installed base of linacs, providing people with the best technology within precision radiation therapy. These replacements will further strengthen our current leading position in the Italian market."

Gustaf Salford, Elekta's President and CEO adds: "I see this as a clear commitment by Europe in general, and Italy specifically, to invest in the health of their people and provide hope in the way of advanced cancer care. Our Versa HD linac, the type to be delivered to Italy, leverages the latest advances in technology to enable sophisticated approaches to treating some of the most common cancers in the region."

The country's public administration procurement office, Consip, managed the public tender. The contract is pending a 35-day standstill period from the announcement of the contract award decision.

###

For further information, please contact:

Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time

Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com
Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 10:10 CET on October 18, 2022.

About Elekta

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm,



Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit [elekta.com](https://www.elekta.com) or follow [@Elekta](https://twitter.com/Elekta) on Twitter.